Myriad offers risk stratification and genomic tools that inform management decisions for every patient you treat, from newly diagnosed to advanced cancer.
Gaining individualized genetic insights about your patient’s prostate cancer gives you valuable information that can help you decide on the best treatment plan for your patient, thereby improving patient outcomes.
Patients with intermediate-risk prostate cancer often fall into the “gray zone,” where decisions between active surveillance and treatment can be difficult. The Prolaris Test was developed for untreated patients with localized prostate cancer providing clear answers to support treatment discussions for low and intermediate-risk patients.1 It outperforms all other biomarkers in identifying which patients may be appropriate to pursue active surveillance (AS).2
No prostate cancer patient deserves the intermediate risk “gray zone”
Learn more about why radiation oncologists order the Prolaris Test for their patients
Men with advanced prostate cancer may qualify for targeted treatments and clinical trials based on their germline and somatic mutation status.3 Combining germline and somatic testing doubles the chances of identifying clinically actionable mutations.4 That’s why clinical guidelines support combined testing:3
Germline testing with the MyRisk Test
Molecular profiling with the Precise Tumor Test
By ordering both tests from Myriad, you get consolidated, concordant results — avoiding the inconsistencies that arise when multiple labs interpret variants differently. Our integrated approach means clearer reporting, fewer redundancies, and greater confidence in distinguishing inherited from somatic mutations, helping you identify more patients for targeted therapies and clinical trials.
The Prolaris Test is a cell-cycle proliferation biomarker test combining clinical and pathological features with a personalized tumor aggressiveness score to help determine if a patient can safely stay on active surveillance or should pursue treatment.
The MyRisk Test is a guideline-driven germline test that identifies inherited mutations in genes like BRCA1 and others, to help determine eligibility for targeted therapies such as PARP inhibitors.3,5
A somatic test with broad coverage of guidelines that analyzes over 500 genes, as well as key biomarkers like MSI, TMB, and PD-L1, to determine eligibility for FDA-approved therapies and clinical trials.6
Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.
Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor
Transparent pricing with personalized cost estimates for the MyRisk Test, financial assistance, and other affordability options, including direct pay. A majority of patients face no out-of-pocket costs for the Prolaris Test.7
Consolidated germline and tumor genomic results are available, on average, 14 days after our lab receives the sample
The Myriad Management Tool streamlines germline and tumor genomic results into an easy-to-follow report
Medical Science Liaisons support providers and their teams in answering clinical, testing, and results-related questions
Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a variant of uncertain significance (VUS) is reclassified and is clinically actionable
The Modern Urologist Podcast: Expert perspectives on precision medicine in urology
Join leading voices in urology as they explore advances in prostate cancer genomics, evolving treatment guidelines, and the future of precision medicine.
In this episode, Dr. Paul Sieber and Ashley Rentisky, PA-C, are joined by Dr. Evan Goldfischer, past president of LUGPA, to address the underutilization of germline and tumor (somatic) testing somatic testing in prostate cancer management. They will discuss challenges practices face in integrating genetic testing into clinical workflows and offer strategies for overcoming barriers.
Tune in for expert insights and actionable advice that can transform prostate cancer care!
Send us a text
Provider Stories: Peer insights from using the Prolaris Test in practice
Hear from fellow clinicians on how the Prolaris Test has changed the way they manage prostate cancer care — helping identify which patients can safely choose active surveillance and which may benefit from treatment.
Robert Jansen, UrologistSouth Carolina
The latest Prolaris report has a great layout. I’m very happy with it. It’s important to me to be able to explain a test report to a patient.
David Rich, UrologistSouth Carolina
I find the utility for Prolaris most helpful in the patients with low risk or immediate risk prostate cancer.
Tim Richardson, UrologistKansas
Prolaris is very helpful with preventing over treating in some of these patients, especially with the intensification of treatment.
Additional clinical resources
Combining germline and somatic testing empowers you to navigate complex decisions in advanced prostate cancer care.
Stay current with clinical validation and utility publications and more.
Find the Myriad documents and forms you need right here.
©2026 Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, Prolaris, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.